Zacks Investment Research
09 Apr 2026, 17:06 UTC · 28w ago
Verdict
Headline takes no side. We score TEM +1.00 across five claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
5 claims · scored −1 bearish … +1 bullish
Tempus AI plans to transition the majority of its xT CDx volume from the lab-developed test version to the FDA-approved version by the end of 2026, unlocking a significant pricing opportunity.
So whatA successful shift to FDA-approved testing secures premium reimbursement rates and provides a clear, structural margin expansion catalyst over the medium term.
More positive than 99% of claims this week
Tempus AI's Diagnostics revenues surged 111.5% year over year in 2025, driven by 26% Oncology volume growth and 29% Hereditary growth.
Triple-digit revenue growth confirms massive commercial traction and market share gains in the core Diagnostics segment, validating the business model for investors.
Continue reading
5 related stories
Top 1 mover · tap to explore
More positive than 98% of claims this week
Tempus AI submitted its xF liquid biopsy to the FDA, creating a longer-term regulatory-driven pricing tailwind.
More positive than 93% of claims this week
Minimal Residual Disease test volume reached approximately 4,700 tests in Q4 2025, up 56% quarter over quarter, but management is prioritizing a measured reimbursement rollout over rapid volume expansion.
More positive than 78% of claims this week
Tempus AI's average selling price in Q4 2025 was approximately $1,640, up about $40 sequentially.
So whatSteady ASP improvement demonstrates early evidence of successful pricing power and the ongoing benefit from the shift toward FDA-approved testing.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Shares surged 17.9% with strong momentum in Data and Applications and robust Diagnostics growth.
More negative than 96% of ticker scores this week
Shares plunged 57.6% over the past year.
More negative than 96% of ticker scores this week
Shares plunged 14.5% over the past year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3d ago
More positive than 32% of relationship scores this week
[mutual] Tempus AI and Omnicell are identified as peers within the Zacks Medical Info Systems industry.
More positive than 32% of relationship scores this week
[mutual] Doximity and Omnicell are identified as peers within the Zacks Medical Info Systems industry.
+42.3%
Price agrees with the score
$67.61 vs $47.50 close before publication (Apr 8) · not market-adjusted
TEM chart →
